BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01131676
First received: May 26, 2010
Last updated: April 7, 2016
Last verified: April 2016
Results First Received: April 7, 2016  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double-Blind;   Primary Purpose: Treatment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773 low dose
Drug: Placebo BI 10773 high dose
Drug: BI 10773 high dose
Drug: Placebo BI 10773 low dose

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients randomised to treatments in 1:1:1 ratio.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Randomisation stratified by:BMI at randomisation(<30/≥30 kg/m2),HbA1c at screening (<8.5%/ ≥8.5%);geographical region(North America including Australia and New Zealand,Latin America,Europe,Africa,Asia);renal function at screening (normal:eGFR ≥90 mL/min, mild impairment:60 mL/min ≤ eGFR ≤89 mL/min, moderate impairment:30 mL/min ≤ eGFR≤59 mL/min).

Reporting Groups
  Description
Placebo Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)
Empagliflozin 10 mg Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)
Empagliflozin 25 mg Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)

Participant Flow for 2 periods

Period 1:   Discontinuation From Treatment
    Placebo     Empagliflozin 10 mg     Empagliflozin 25 mg  
STARTED     2337 [1]   2347 [1]   2344 [1]
COMPLETED     1650 [2]   1790 [2]   1800 [2]
NOT COMPLETED     687     557     544  
Study drug stopped, reason missing                 5                 3                 4  
Not treated                 4                 2                 2  
Lack of Efficacy                 11                 1                 0  
Non compliant with protocol                 15                 15                 12  
Lost to Follow-up                 15                 9                 6  
Refusal to continue, not due to AE                 172                 118                 122  
Other than those specified                 162                 142                 125  
Adverse Event                 303                 267                 273  
[1] Randomised
[2] Not prematurely discontinued from trial medication

Period 2:   Discontinuation From Study (Treated Set)
    Placebo     Empagliflozin 10 mg     Empagliflozin 25 mg  
STARTED     2333     2345     2342  
Final Vital Status (VS) Available     2316     2324     2327  
COMPLETED     2266 [1]   2264 [1]   2279 [1]
NOT COMPLETED     67     81     63  
Consent withdrawn: Final VS available                 23                 35                 25  
Consent withdrawn:Final VS not available                 8                 6                 5  
Site closure: Final VS available                 20                 21                 19  
Site closure:Final VS not available (NA)                 5                 9                 7  
Lost to FU for 3PMACE:Final VS available                 7                 6                 5  
Lost to FU for 3P-MACE:Final VS NA                 4                 4                 2  
[1] Completed the trial or died



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Treated set (TS): Consists of all randomised patients who received at least 1 dose of study medication. Patients were assigned to treatment groups according to the randomisation scheme.

Reporting Groups
  Description
Placebo Oral administration of Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily)
Empagliflozin 10 mg Oral administration of Empagliflozin 10 mg (BI 10773) film coated tablets (1 tablet once daily)
Empagliflozin 25 mg Oral administration of Empagliflozin 25 mg (BI 10773) film coated tablets (1 tablet once daily)
Total Total of all reporting groups

Baseline Measures
    Placebo     Empagliflozin 10 mg     Empagliflozin 25 mg     Total  
Number of Participants  
[units: participants]
  2333     2345     2342     7020  
Age  
[units: years]
Mean (Standard Deviation)
  63.2  (8.8)     63.0  (8.6)     63.2  (8.6)     63.1  (8.6)  
Gender  
[units: participants]
       
Female     653     692     659     2004  
Male     1680     1653     1683     5016  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

2.  Secondary:   Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

3.  Secondary:   Percentage of Participants With Silent MI   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

4.  Secondary:   Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

5.  Secondary:   Percentage of Participants With New Onset Albuminuria   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

6.  Secondary:   Percentage of Participants With New Onset Macroalbuminuria   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]

7.  Secondary:   Percentage of Participants With the Composite Microvascular Outcome   [ Time Frame: From randomisation to individual end of observation, up to 4.6 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
2 sets of duplicates(4 patients(pts)) were counted only once.652 sites were initiated and 611 enrolled.One site transferred all pts to other sites.27 pts randomised and 13 pts screened were excluded from analyses due to serious non-compliance


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim
phone: 800-243-0127 ext +1
e-mail: clintriage.rdg@boehringer-ingelheim.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01131676     History of Changes
Other Study ID Numbers: 1245.25
2009-016178-33 ( EudraCT Number: EudraCT )
Study First Received: May 26, 2010
Results First Received: April 7, 2016
Last Updated: April 7, 2016
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Australia: Responsible Ethics Committee
Austria: Medicines and Medical Devices Agency
Belgium: Federal Agency for Medicinal and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Croatia: Agency for Medicinal Product and Medical Devices
Czech Republic: State Institute for Drug Control
Denmark: The Danish Health and Medicines Authority
Estonia: The State Agency of Medicine
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Georgia: Ministry of Health
Greece: Ethics Committee
Hong Kong: Department of Health
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India
Indonesia: National Agency of Drug and Food Control
Israel: Israeli Health Ministry Pharmaceutical Administration
Italy: Ethics Committee
Japan: Ministry of Health, Labor and Welfare
Malaysia: Ministry of Health
Mexico: Federal Commission for Protection Against Health Risks
Netherlands: Central Committee Research Involving Human Subjects
New Zealand: Medsafe
Norway: Norwegian Medicines Agency
Peru: General Directorate of Pharmaceuticals, Devices, and Drugs
Philippines: Bureau of Food and Drugs
Poland: Registration Medicinal Product Medical Device Biocidal Product
Portugal: National Pharmacy and Medicines Institute
Romania: National Medicines Agency
Russia: Pharmacological Committee, Ministry of Health
Singapore: Health Sciences Authority
South Africa: Medicines Control Council
South Korea: Ministry of Food and Drug Safety (MFDS)
Spain: Spanish Agency of Medicines
Sri Lanka: Ministry of Healthcare and Nutrition
Taiwan : Food and Drug Administration
Thailand: Food and Drug Administration
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration